These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 10914739

  • 1. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 2. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE, Mayer LD.
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [Abstract] [Full Text] [Related]

  • 4. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
    Lopes de Menezes DE, Hu Y, Mayer LD.
    J Exp Ther Oncol; 2003 Jan; 3(2):72-82. PubMed ID: 12822513
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB.
    Clin Cancer Res; 2004 Nov 15; 10(22):7662-70. PubMed ID: 15569999
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI.
    Clin Cancer Res; 2002 Mar 15; 8(3):679-83. PubMed ID: 11895895
    [Abstract] [Full Text] [Related]

  • 8. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 15; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM.
    Leukemia; 2003 Jan 15; 17(1):211-9. PubMed ID: 12529680
    [Abstract] [Full Text] [Related]

  • 11. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS.
    Br J Haematol; 2004 Dec 15; 127(5):519-30. PubMed ID: 15566355
    [Abstract] [Full Text] [Related]

  • 12. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C.
    Clin Cancer Res; 2005 Mar 01; 11(5):1990-8. PubMed ID: 15756025
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE.
    J Clin Oncol; 2004 Mar 15; 22(6):1110-7. PubMed ID: 15020613
    [Abstract] [Full Text] [Related]

  • 14. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 15; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.
    Cancer Res; 2000 Dec 15; 60(24):6950-7. PubMed ID: 11156395
    [Abstract] [Full Text] [Related]

  • 16. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C, Wellham LL.
    Anticancer Res; 2003 Dec 15; 23(3B):2681-90. PubMed ID: 12894558
    [Abstract] [Full Text] [Related]

  • 17. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR.
    Semin Oncol; 2003 Apr 15; 30(2):300-4. PubMed ID: 12720157
    [Abstract] [Full Text] [Related]

  • 18. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S, Inui M, Kamei T, Nakase M, Okumura K, Tagawa T.
    Oncol Rep; 2006 Jun 15; 15(6):1563-8. PubMed ID: 16685396
    [Abstract] [Full Text] [Related]

  • 19. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Römmele M, Leja A, Baudler M, Benimetskaya L, Gonser B, Pieles U, Maier T, Wagner T, Sanders K, Beck JF, Hanauer G, Stein CA.
    Oligonucleotides; 2006 Jun 15; 16(1):83-93. PubMed ID: 16584297
    [Abstract] [Full Text] [Related]

  • 20. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
    Wacheck V, Krepler C, Strommer S, Heere-Ress E, Klem R, Pehamberger H, Eichler HG, Jansen B.
    Antisense Nucleic Acid Drug Dev; 2002 Dec 15; 12(6):359-67. PubMed ID: 12568310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.